Shire gets pumped on new platform delivery tech

Shire says its new pump delivery technology could keep the company on the bleeding-edge of the rare disease field. A small study of a device that is implanted in patients' spines and tasked to pump drugs to the brain could go a long way to helping extend the product life cycle of a drug like Elaprase. "It sounds very exciting, like they're really being smart about life cycle management of their existing franchises," Navid Malik, an analyst at Merchant Securities, tells Bloomberg. "If they can do the same with other rare disease areas that are affecting the brain, they could have a nice platform technology here." Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.